Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ponatinib vs Nilotinib in Imatinib-Resistant CP-CML
NCT02627677Phase 3Terminated
- Sponsor
- ARIAD Pharmaceuticals, Inc.
- Start
- Dec 2015
- Primary completion
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ponatinib in chronic myeloid leukemia (CML) (3 arms), sponsored by ARIAD Pharmaceuticals, Inc. Primary endpoint: Major Molecular Response at 12 months. Started Dec 2015; status: terminated.
02
Drugs
ponatinib
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT02627677.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02627677.